Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
Pfizer Secures $10 Billion Deal for Obesity Drug Developer Metsera, Outbids Novo Nordisk 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Eli Lilly Becomes First Pharma Giant to Hit $1 Trillion Amid Soaring Weight-Loss Drug Demand 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Eli Lilly announced that its obesity drug Zepbound outperformed Novo Nordisk’s Wegovy in a direct comparison across five key weight-loss metrics, including waist circumference reduction. Results from the first-ever head-to-head trial were presented at the European Congress on Obesity and confirmed Zepbound's superior efficacy.
Previously reported in December, the trial had already shown that Zepbound led to 47% more weight loss than Wegovy. According to full data released Sunday, nearly 25% more participants lost over 15% of their body weight with Zepbound compared to Wegovy.
The study revealed Zepbound users experienced an average waist reduction of 18.4 centimeters, versus 13 centimeters for those on Wegovy. Zepbound, which mimics two gut hormones, has a dual mechanism of action, while Wegovy targets just one. This biological advantage may explain the enhanced weight loss results.
Both drugs had previously received U.S. FDA approval based on separate clinical trials—Zepbound achieved over 22% weight loss after 72 weeks, while Wegovy showed 15% loss after 68 weeks. The obesity drug market is expected to surpass $150 billion annually by the next decade, making these results crucial as Eli Lilly seeks broader insurance coverage.
The new data comes shortly after CVS Health (NYSE:CVS) dropped Zepbound from some reimbursement lists in favor of Wegovy. However, these trial findings may bolster Lilly’s position in payer negotiations and strengthen its commercial appeal.
With growing demand for effective weight-loss treatments, Zepbound’s performance positions it as a formidable competitor in the fast-growing obesity drug market, challenging Wegovy’s dominance with robust clinical backing and enhanced patient outcomes.
